

Antenatal mitochondrial disease caused by mitochondrial ribosomal protein (*MRPS22*) mutation

A Saada, A Shaag, S Arnon, T Dolfín, C Miller, D Fuchs-Telem, A Lombes, O Elpeleg

J Med Genet 2007;**44**:784–786. doi: 10.1136/jmg.2007.053116

Three patients born to the same set of consanguineous parents presented with antenatal skin oedema, hypotonia, cardiomyopathy and tubulopathy. The enzymatic activities of multiple mitochondrial respiratory chain complexes were reduced in muscle. Marked reduction of 12s rRNA, the core of the mitochondrial small ribosomal subunit, was found in fibroblasts. Homozygosity mapping led to the identification of a mutation in the *MRPS22* gene, which encodes a mitochondrial ribosomal protein. Transfection of the patient cells with wild-type *MRPS22* cDNA increased the 12s rRNA content and normalised the enzymatic activities. Quantification of mitochondrial transcripts is advisable in patients with multiple defects of the mitochondrial respiratory chain.

Of the 85 mitochondrial respiratory chain subunits, 13 are synthesised within the organelle by the mitochondrial ribosome. This translation apparatus consists of two ribosomal RNA (rRNA) transcripts encoded by the mitochondrial genome, and nearly 80 nuclear-encoded ribosomal proteins. In addition to the 22 mitochondrial-encoded transfer RNAs (tRNAs), mitochondrial translation requires a large set of imported proteins, including translation factors, aminoacyl-tRNA synthetases and tRNA modification enzymes. Defects in nuclear-encoded components of the mitochondrial protein synthesis machinery are found in 5–10% of infants referred for enzymatic investigations of the oxidative phosphorylation system in muscle.^{1,2} We now describe a new defect in the mitochondrial ribosome, present before birth.

Two female babies, born at term to consanguineous parents (first cousins), presented within hours of birth with severe muscle hypotonia, marked lactic acidemia and hyperammonaemia. The pregnancies were uneventful, but at around 36 weeks of gestation, fetal sonography revealed generalised oedema, especially at the neck, labia, palms and feet. At birth, there was prominent subcutaneous oedema and ascites (fig 1). Hypertrophic cardiomyopathy and tubulopathy developed in the first week and the patients died at 2–22 days of age.



Figure 1 Patient 3 at 4 hours of age. Parental/guardian informed consent was obtained for publication of this figure.

In the muscle mitochondria of the first affected infant, the enzymatic activities of the respiratory chain complexes I, III, IV (COX) and V were reduced to 8–30% of the control mean. The activity of complex II, the only complex that is encoded solely by the nuclear genome, was normal. A muscle biopsy from the second patient was denied, but COX activity in lymphocytes was reduced to 47–62%. Based on the enzymatic findings, a defect in the synthesis of the mitochondrial-encoded proteins was assumed. Initially, Southern blot analysis of muscle DNA revealed normal sized mtDNA but decreased mtDNA content, suggesting mtDNA depletion.³ A similarly affected daughter was recently born, enabling homozygosity mapping analysis in the family, concomitant with revision of the molecular studies. Re-evaluating the mtDNA content by means of real-time quantitative PCR (qPCR) with an expanded age-matched control range, found a normal mtDNA:nuclear DNA ratio in the muscle of the first patient.

To investigate whether a defect in mitochondrial transcription is responsible for the multiple enzymatic defects, three mitochondrial transcripts, COX2 mRNA, 12s rRNA and 16s rRNA, were quantified in the patients' fibroblasts using real-time qPCR. The analysis revealed a striking reduction of 12s rRNA content to 10% of the control mean and a moderate reduction of 16s rRNA and COX2 mRNA to 41% and 45% of the control mean, respectively. Notably, the sequence of the 12s rRNA was similar to the consensus sequence (<http://www.mitomap.org/>).

Bacterial rRNAs are stable only if incorporated into the ribosomal subunits;⁴ we therefore speculate that the markedly reduced 12S rRNA level was the result of a defect in one of the 29 proteins that, together with the 12s rRNA, constitute the small subunit of the mitochondrial ribosome.⁵

The search for homozygous regions using the Affymetrix Human Mapping 50K Array Xba240 (Affymetrix, Santa Clara, California, USA) in DNA samples of the affected patients, performed as described previously,⁶ revealed a single, large genomic homozygous region on chromosome 3 at 118.723–174.963 Mb (marker rs1381801–rs1352416). The result was verified by genotyping a set of polymorphic microsatellite markers that spanned the region (D3S1267, D3S1292, D3S1569, D3S1279, D3S1594, D3S1264 and D3S1614). The three patients were homozygous for all the markers, whereas the parents and their healthy daughter were heterozygous for the same allele. This large region encompasses 442 open-reading frames, of which 7 were annotated as mitochondrial, including MRPL3, mitochondrial elongation factor G1 (which were both sequenced and found to be normal), and *MRPS22*. The latter gene encodes a protein of 319 amino acids. Sequence determination of its cDNA revealed a G→A substitution at position 509, which is predicted to replace a highly conserved arginine in codon 170 by histidine (fig 2A–D). The three patients were homozygous, and the parents and their healthy

Abbreviations: qPCR, quantitative PCR; tRNA, transfer RNA




Figure 2 MRPS22 mutation, conservation of the mutated residue and restoration of the 12s rRNA level in patient cells. (A) MRPS22 DNA sequence analysis of the patient showing a G nucleotide at position 509 (arrow). Note an A nucleotide at this position in (B) a healthy control and an A/G in (C) the mother's sequence, disclosing a carrier state. (D) The mutation affects a highly conserved arginine at codon 170 (marked by an asterisk) in the amino acid sequence of the patient (Pt) amino acid. Interspecies comparison of the amino acids bordering the mutation between human (HS), mouse (MM), honeybee (AM; *Apis mellifera*), fruitfly (DM; *Drosophila melanogaster*) and the worm *Caenorhabditis elegans* (CE) (protein C14A4.2), shows the conservation. (E) The 12s rRNA transcript level in: bar 1, control cells; bar 2, patient cells; bar 3, patient cells transfected with an empty lentiviral construct; bar 4, patient cells transfected with a construct containing the wild-type MRPS22 cDNA. Results are expressed as a percentage of the control mean.

daughter were heterozygous for the mutation, which was not present in 52 ethnically matched controls. Because the MRPS22 protein has no counterpart in the *Escherichia coli* ribosome, and the functional domains are not recognised, the pathogenic potential of this mutation was unclear.

To address this question, the normal MRPS22 cDNA was cloned into a pLenti6/V5-D-TOPO 6969-bp expression vector by directional TOPO cloning (Invitrogen Corp., Carlsbad, California, USA). The recombinant vector was propagated in 293FT cells according to the manufacturer's instructions (ViraPower; Invitrogen). The patient cells were infected with the recombinant virus, and stably transduced cells were selected by blasticin. The 12s rRNA content in patient cells infected with the MRPS22 construct was 34 (4)% of the control mean, whereas in cells infected with an empty vector, the 12s rRNA content was 10 (4)% (fig 2E). The enzymatic activity of COX concomitantly increased from 27–33% to 77–92% of the control mean. Both 12S rRNA content and COX activity remained unchanged in patient cells that were transfected with the empty viral construct. These experiments established the pathogenic role of the mutated MRPS22 protein.

Defects in nuclear-encoded components of the translation system comprise a novel group of mitochondrial respiratory chain defects. The patients may appear normal at birth^{7,8} but may also display intrauterine growth retardation, dysmorphic signs and cerebral malformations.^{8,9} It is of interest that the first reported patient with a defect in the mitochondrial ribosome was also born with subcutaneous oedema.¹

The MRPS22 gene is the second ribosomal protein involved in mitochondrial disease in humans, and this is the first report of a mutation in this gene. The study underlines the superiority of real-time qPCR over Southern blot for mtDNA quantification; the former requires a smaller amount of tissue and is far more accurate. Our findings also highlight the usefulness of mitochondrial transcript quantification, which directed us to a single gene within a very large chromosomal region.

ACKNOWLEDGEMENTS

We gratefully acknowledge the collaboration of the patients' family, Dr Mira Korner of the National Center of Genomic Technologies, at the

Hebrew University, Jerusalem, and Corinne Belaiche for OXPHOS analysis. This work was supported in part by the Association Française contre les Myopathies (AFM), by the Israel Science Foundation (grant 1354-2005), France-Israel Ministries of Science (grant no 3-904) and by the US-Israel Binational Science Foundation (grant 032-2005).

Authors' affiliations

A Saada, A Shaag, C Miller, D Fuchs-Telem, O Elpeleg, The Metabolic Disease Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel

S Arnon, T Dolfin, Department of Neonatology, Meir Medical Center, Kfar Saba, Israel

A Lombes, INSERM 582, Hôpital de La Salpêtrière, Paris, France

Competing interests: none declared.

Parental/guardian informed consent was obtained for publication of fig 1.

Correspondence to: Professor O Elpeleg, Metabolic Disease Unit, Hadassah - Hebrew University Medical Center, Jerusalem, 91120, Israel; elpeleg@cc.huji.ac.il

Received 16 July 2007

Revised 28 July 2007

Accepted 21 August 2007

Published Online First 7 September 2007

REFERENCES

- Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag A, Hershkovitz E, Elpeleg O. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. *Ann Neurol* 2004;**56**:734–8.
- Sarzi E, Bourdon A, Chretien D, Zarhrate M, Corcos J, Slama A, Cormier-Daire V, de Lonlay P, Munnich A, Rotig A. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. *J Pediatr* 2007;**150**:531–4.
- Arnon S, Aviram R, Dolfin T, Regev R, Litmanovits I, Tepper R, Elpeleg O. Mitochondrial DNA depletion presenting prenatally with skin edema and multisystem disease immediately after birth. *Prenat Diagn* 2002;**22**:34–7.
- Dennis PP, Young RF. Regulation of ribosomal protein synthesis in *Escherichia coli* B/r. *J Bacteriol* 1975;**121**:994–9.
- Cavdar Koc E, Burkhart W, Blackburn K, Moseley A, Spremulli LL. The small subunit of the mammalian mitochondrial ribosome. Identification of the full complement of ribosomal proteins present. *J Biol Chem* 2001;**276**:19363–74.

- 6 **Edvardson S**, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, Saada A, Elpeleg O. Deleterious mutation in the mitochondrial arginyl-tRNA synthetase gene is associated with ponto-cerebellar hypoplasia. *Am J Hum Genet* 2007;**81**:857–62.
- 7 **Smeitink JA**, Elpeleg O, Antonicka H, Diepstra H, Saada A, Smits P, Sasarman F, Vriend G, Jacob-Hirsch J, Shaag A, Rechavi G, Welling B, Horst J, Rodenburg RJ, van den Heuvel B, Shoubbridge EA. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. *Am J Hum Genet* 2006;**79**:869–77.
- 8 **Valente L**, Tiranti V, Marsano RM, Malfatti E, Fernandez-Vizarra E, Donnini C, Mereghetti P, De Gioia L, Burlina A, Castellan C, Comi GP, Savasta S, Ferrero I, Zeviani M. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. *Am J Hum Genet* 2007;**80**:44–58.
- 9 **Coenen MJ**, Antonicka H, Ugalde C, Sasarman F, Rossi R, Heister JG, Newbold RF, Trijbels FJ, van den Heuvel LP, Shoubbridge EA, Smeitink JA. Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. *N Engl J Med* 2004;**351**:2080–6.

BMJ Clinical Evidence—Call for contributors

BMJ Clinical Evidence is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. *BMJ Clinical Evidence* needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

Areas for which we are currently seeking contributors:

- Secondary prevention of ischaemic cardiac events
- Acute myocardial infarction
- MRSA (treatment)
- Bacterial conjunctivitis

However, we are always looking for contributors, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *BMJ Clinical Evidence* editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *BMJ Clinical Evidence* in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months.

In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for *BMJ Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

BMJ Clinical Evidence also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to *BMJ Clinical Evidence* for 3 months for each review.

If you are interested in becoming a peer reviewer for *BMJ Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com/cweb/contribute/peerreviewer.jsp